March 27th, 2022 (Earnings Report)Dear Reader,We just identified several healthtech stocks that are expected to release earnings this week.If you are interested in any of these companies, we encourage you to do your own research and due diligence before pursuing any investments.Keep in mind, the actual earnings date and time may change, so if you’re interested in any of these companies you will need to pay close attention to their announcements.
Acumen Pharmaceuticals
Symbol: ABOS
Recent Price: $5.14
Average Analyst Price Target: $15.50 (201.56%)
Market Cap: $208.02M
Last Year's EPS: ―
Consensus EPS Forecast: -$0.14
Expected Earnings Date: Mar 27 2022
Recent Analyst Action: Paul Matteis, analyst at Stifel Nicolaus, reiterates coverage on Acumen Pharmaceuticals (ABOS) in the Healthcare sector with a Buy rating and a price target of $ 17 (2 weeks ago).
TipRanks.com also reports that Acumen Pharmaceuticals currently has 2 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $15.50 . The target pricing ranges from a high forecast of $17.00 down to a low forecast of $14.00. Acumen Pharmaceuticals (ABOS)’s last closing price was $5.14 which would put the average price target at 201.56% upside.Here are 3rd party ratings for ABOS:
- TipRanks.com: Moderate Buy
- TradingView.com: Strong Sell
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: n/a
- Zacks.com: Buy, Bottom 36% (161 out of 252)
--------------------------------------------------------------------------
AKOUOS
Symbol: AKUS
Recent Price: $4.81
Average Analyst Price Target: $30.00 (523.70%)
Market Cap: $165.92M
Last Year's EPS: -$0.37
Consensus EPS Forecast: -$0.66
Expected Earnings Date: Mar 27 2022
Recent Analyst Action: Robert Hazlett, analyst at BTIG, reiterates coverage on AKOUOS (AKUS) in the Healthcare sector with a Buy rating and a price target of $ 35 (1 month ago).
TipRanks.com also reports that AKOUOS currently has 2 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $30.00 . The target pricing ranges from a high forecast of $35.00 down to a low forecast of $25.00. AKOUOS (AKUS)’s last closing price was $4.81 which would put the average price target at 523.70% upside.Here are 3rd party ratings for AKUS:
- TipRanks.com: Moderate Buy
- TradingView.com: Sell
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Hold, Bottom 36% (161 out of 252)
--------------------------------------------------------------------------
Aveanna Healthcare Holdings
Symbol: AVAH
Recent Price: $5.24
Average Analyst Price Target: $10.50 (100.38%)
Market Cap: $965.02M
Last Year's EPS: $0.09
Consensus EPS Forecast: $0.11
Expected Earnings Date: Mar 27 2022
Recent Analyst Action: Brian Tanquilut, analyst at Jefferies, reiterates coverage on Aveanna Healthcare Holdings (AVAH) in the Healthcare sector with a Buy rating and a price target of $ 11 (1 month ago).
TipRanks.com also reports that Aveanna Healthcare Holdings currently has 2 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $10.50 . The target pricing ranges from a high forecast of $11.00 down to a low forecast of $10.00. Aveanna Healthcare Holdings (AVAH)’s last closing price was $5.24 which would put the average price target at 100.38% upside.Here are 3rd party ratings for AVAH:
- TipRanks.com: Moderate Buy
- TradingView.com: Sell
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Hold, Bottom 8% (233 out of 252)
--------------------------------------------------------------------------
CASI Pharmaceuticals
Symbol: CASI
Recent Price: $0.8503
Average Analyst Price Target: n/a ()
Market Cap: $105.39M
Last Year's EPS: -$0.12
Consensus EPS Forecast: -$0.06
Expected Earnings Date: Mar 27 2022
Recent Analyst Action: Sean Lee, analyst at H.C. Wainwright, reiterates coverage on CASI Pharmaceuticals (CASI) in the Healthcare sector with a Buy rating and a price target of n/a (1 month ago).
TipRanks.com also reports that CASI Pharmaceuticals currently has n/a analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is n/a . The target pricing ranges from a high forecast of n/a down to a low forecast of n/a. CASI Pharmaceuticals (CASI)’s last closing price was $0.8503 which would put the average price target at upside.Here are 3rd party ratings for CASI:
- TipRanks.com: Moderate Buy
- TradingView.com: Buy
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Weak sell
- Zacks.com: Hold, Bottom 35% (163 out of 252)
--------------------------------------------------------------------------
Cue Biopharma
Symbol: CUE
Recent Price: $5.01
Average Analyst Price Target: $24.17 (382.44%)
Market Cap: $165.38M
Last Year's EPS: -$0.37
Consensus EPS Forecast: -$0.26
Expected Earnings Date: Mar 27 2022
Recent Analyst Action: Reni Benjamin, analyst at JMP Securities, reiterates coverage on Cue Biopharma (CUE) in the Healthcare sector with a Buy rating and a price target of $ 15 (4 days ago).
TipRanks.com also reports that Cue Biopharma currently has 7 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $24.17 . The target pricing ranges from a high forecast of $30.00 down to a low forecast of $15.00. Cue Biopharma (CUE)’s last closing price was $5.01 which would put the average price target at 382.44% upside.Here are 3rd party ratings for CUE:
- TipRanks.com: Strong Buy
- TradingView.com: Sell
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Hold, Bottom 36% (161 out of 252)
--------------------------------------------------------------------------
Ginkgo Bioworks Holdings
Symbol: DNA
Recent Price: $3.66
Average Analyst Price Target: $9.70 (165.03%)
Market Cap: $6.12B
Last Year's EPS: $0
Consensus EPS Forecast: -$0.04
Expected Earnings Date: Mar 27 2022
Recent Analyst Action: Steven Mah, analyst at Cowen & Co., reiterates coverage on Ginkgo Bioworks Holdings (DNA) in the Healthcare sector with a Buy rating and a price target of $ 12 (3 weeks ago).
TipRanks.com also reports that Ginkgo Bioworks Holdings currently has 5 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $9.70 . The target pricing ranges from a high forecast of $12.00 down to a low forecast of $6.00. Ginkgo Bioworks Holdings (DNA)’s last closing price was $3.66 which would put the average price target at 165.03% upside.Here are 3rd party ratings for DNA:
- TipRanks.com: Moderate Buy
- TradingView.com: Sell
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Hold, Bottom 36% (161 out of 252)
--------------------------------------------------------------------------
Mind Medicine
Symbol: MNMD
Recent Price: $1.18
Average Analyst Price Target: $2.99 (153.81%)
Market Cap: $497.02M
Last Year's EPS: -$0.05
Consensus EPS Forecast: -$0.05
Expected Earnings Date: Mar 27 2022
Recent Analyst Action: Michael Okunewitch, analyst at Maxim Group, reiterates coverage on Mind Medicine (MNMD) in the Healthcare sector with a Buy rating and a price target of $ 3 (1 month ago).
TipRanks.com also reports that Mind Medicine currently has 1 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $2.99 . The target pricing ranges from a high forecast of $3.00 down to a low forecast of $3.00. Mind Medicine (MNMD)’s last closing price was $1.18 which would put the average price target at 153.81% upside.Here are 3rd party ratings for MNMD:
- TipRanks.com: Moderate Buy
- TradingView.com: Neutral
- Yahoo! Finance: Neutral Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: n/a, n/a
--------------------------------------------------------------------------
PAVmed
Symbol: PAVM
Recent Price: $1.59
Average Analyst Price Target: $6.00 (277.36%)
Market Cap: $139.82M
Last Year's EPS: -$0.17
Consensus EPS Forecast: -$0.16
Expected Earnings Date: Mar 27 2022
Recent Analyst Action: Ross Osborn, analyst at Cantor Fitzgerald, reiterates coverage on PAVmed (PAVM) in the Healthcare sector with a Buy rating and a price target of $ 6 (1 month ago).
TipRanks.com also reports that PAVmed currently has 1 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $6.00 . The target pricing ranges from a high forecast of $6.00 down to a low forecast of $6.00. PAVmed (PAVM)’s last closing price was $1.59 which would put the average price target at 277.36% upside.Here are 3rd party ratings for PAVM:
- TipRanks.com: Moderate Buy
- TradingView.com: Neutral
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: sell
- Zacks.com: Hold, Bottom 31% (173 out of 252)
--------------------------------------------------------------------------
Pear Therapeutics
Symbol: PEAR
Recent Price: $4.38
Average Analyst Price Target: $12.00 (173.97%)
Market Cap: $603.56M
Last Year's EPS: ―
Consensus EPS Forecast: -$0.41
Expected Earnings Date: Mar 27 2022
Recent Analyst Action: Marie Thibault, analyst at BTIG, reiterates coverage on Pear Therapeutics (PEAR) in the Healthcare sector with a Buy rating and a price target of $ 12 (3 days ago).
TipRanks.com also reports that Pear Therapeutics currently has 4 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $12.00 . The target pricing ranges from a high forecast of $13.00 down to a low forecast of $11.00. Pear Therapeutics (PEAR)’s last closing price was $4.38 which would put the average price target at 173.97% upside.Here are 3rd party ratings for PEAR:
- TipRanks.com: Strong Buy
- TradingView.com: Sell
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: sell
- Zacks.com: Hold, Bottom 35% (163 out of 252)
--------------------------------------------------------------------------
Progenity
Symbol: PROG
Recent Price: $1.69
Average Analyst Price Target: $42.00 (2385.21%)
Market Cap: $276.74M
Last Year's EPS: -$1.53
Consensus EPS Forecast: -$0.16
Expected Earnings Date: Mar 27 2022
Recent Analyst Action: Joseph Pantginis, analyst at H.C. Wainwright, reiterates coverage on Progenity (PROG) in the Healthcare sector with a Buy rating and a price target of n/a (2 weeks ago).
TipRanks.com also reports that Progenity currently has 2 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $42.00 . The target pricing ranges from a high forecast of $42.00 down to a low forecast of $42.00. Progenity (PROG)’s last closing price was $1.69 which would put the average price target at 2385.21% upside.Here are 3rd party ratings for PROG:
- TipRanks.com: Moderate Buy
- TradingView.com: Buy
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: sell
- Zacks.com: Hold, Bottom 35% (163 out of 252)
--------------------------------------------------------------------------
Venus Concept
Symbol: VERO
Recent Price: $1.38
Average Analyst Price Target: $7.00 (407.25%)
Market Cap: $88.30M
Last Year's EPS: -$0.34
Consensus EPS Forecast: -$0.1
Expected Earnings Date: Mar 27 2022
Recent Analyst Action: Marie Thibault, analyst at BTIG, reiterates coverage on Venus Concept (VERO) in the Healthcare sector with a Buy rating and a price target of $ 7 (2 months ago).
TipRanks.com also reports that Venus Concept currently has 1 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $7.00 . The target pricing ranges from a high forecast of $7.00 down to a low forecast of $7.00. Venus Concept (VERO)’s last closing price was $1.38 which would put the average price target at 407.25% upside.Here are 3rd party ratings for VERO:
- TipRanks.com: Moderate Buy
- TradingView.com: Sell
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Hold, Bottom 31% (173 out of 252)
To Your Financial Future,
The Editor, HealthTechMovers.com
